,23,24,25 KRAS mutation-mediated signaling enhances cancer cell competitiveness and reduces therapeutic susceptibility by increasing glucose uptake and hexokinase activity, promoting pathways such as glycolysis, the TCA cycle, and PPP.17 This evidence concerns the gene KRAS and cancer.